UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549


                                   FORM 10-QSB

[X]  Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange
     Act of 1934

         For the quarterly period ended March 31, 1999

[  ] Transition Report pursuant to 13 or 15(d) of the Securities  Exchange Act
     of 1934

         For the transition period from                       to

Commission File Number 001-14297

                                MW Medical, Inc.
        (Exact name of Small Business Issuer as specified in its charter)

                        Nevada                               86-0907471
            (State or other jurisdiction of                  (IRS Employer
                    incorporation )                          Identification No.)

         6955 East Caballo Drive
        Paradise Valley, Arizona                             85253
(Address of principal executive offices)                 (Zip Code)

Issuer's telephone number, including area code:  (602) 483-8700

Indicate by a check mark  whether the issuer (1) has filed all reports  required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days. [X] Yes [ ] No

Indicate the number of shares  outstanding  of each of the  issuer's  classes of
common stock, as of the latest practicable date.

             Class                           Outstanding as of March 31, 1999
------------------------------------        -----------------------------------
$.001 par value Class A Common Stock                15,873,929 shares




<PAGE>



                         PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

BASIS OF PRESENTATION

General

     The  accompanying  unaudited  financial  statements  have been  prepared in
accordance with the instructions to Form 10-QSB and,  therefore,  do not include
all information and footnotes necessary for a complete presentation of financial
position,  results  of  operations,  cash  flows,  and  stockholders'  equity in
conformity  with generally  accepted  accounting  principles.  In the opinion of
management,  all adjustments considered necessary for a fair presentation of the
results of  operations  and  financial  position have been included and all such
adjustments are of a normal recurring  nature.  Operating  results for the three
months ended March 31, 1999, are not necessarily  indicative of the results that
can be expected for the year ending December 31, 1999.

Item 2. Management's  Discussion and Analysis of Financial Condition and Results
        of Operations.

     MW Medical,  Inc.  (the  "Company")  is in the  business of  designing  and
developing  microwave  technologies for dermatological  applications through its
wholly owned subsidiary,  Microwave Medical Corporation ("MMC"). MMC established
an office in Germany in late  1997,  called  Microwave  Medical  GmBH  ("GmBH").
Testing in Germany was concluded in July 1998. The Company's products are in the
development stage. The Company plans to market and sell its microwave technology
products upon completion of the development stage.

     The Company is a Nevada  corporation  and was  incorporated  on December 4,
1997. The Company was originally the owner of two wholly owned subsidiaries:

     (A)  Microwave Medical Corporation, a California corporation ("MMC");

     (B)  P&H Laboratories, Inc., a California corporation ("P&H").

Sale of the Business of P&H

     The Company has sold the business of P&H pursuant to an asset  purchase and
sale  agreement  dated  March 9, 1998  between P&H and  Microwave  Communication
Corporation, a California corporation ("Microwave"),  whereby P&H agreed to sell
to Microwave  all of the assets of the  business of P&H as a going  concern (the
"P&H Sale  Agreement").  The sale of assets by P&H to Microwave was completed on
May 6, 1998. The following consideration was received by the Company on closing:

     (A)  cash consideration of $160,943;

     (B)  a promissory note issued by MCC/ Ferro Systems,  Inc., a subsidiary of
          Microwave,  whereby  MCC/Ferro  has  agreed  to pay to P&H  the sum of
          $250,000  on August 1, 1998 and the sum of  $243,125 on March 31, 1999
          (the "MCC/Ferro  Promissory  Note");  P&H has assigned the note to the
          Company;

     (C)  the  agreement  of Microwave to provide to MMC 1200 hours of microwave
          related services for the period to April 1, 1999, subject to a maximum
          of 100 hours per month;



<PAGE>




     (D)  office space for the business of MMC at  MCC/Ferro's  facility in Simi
          Valley, California until February 28, 1999.

     The  obligations  of  MCC/Ferro  under the MCC/ Ferro  Promissory  Note are
secured by a general security  agreement against the assets of MCC/Ferro and the
guarantee of Microwave.  The general security  agreement is subordinated to bank
financing  arranged by MCC/Ferro  to pay-out  P&H's bank  financing  and pay the
amounts under the MCC/Ferro Promissory Note.

     The payment was not received on March 31, 1999. The Company has recorded an
allowance for doubtful accounts of $60,000 and extended the repayment terms. MCC
is to make  monthly  payments of $15,000  including  interest at 8% beginning in
July on the principal balance of $243,125.

LIQUIDITY AND CAPITAL RESOURCES

     As  of  March  31,  1999,  the  Company  had  $736,407  in  cash  and  cash
equivalents.  During the  quarter,  the Company  received  cash of $101,250  and
incurred capital raising costs of $11,250 in connection with the sale of 150,000
shares of the Company's  restricted  common stock.  Loss per share from research
operations,   general  and   administrative   expenses  and   depreciation   and
amortization was $.02.

Item 5. Other Information.

Microwave Medical Corporation (MMC)

     The Company's wholly owned  subsidiary,  MMC, is engaged in the development
of proprietary  technology  relating to the use of microwave  energy for medical
applications.  MMC has a patent  pending  entitled,  "Method and  Apparatus  for
Treating Subcutaneous  Histological Features",  which focuses on the application
of  microwave  energy  to the  treatment  of  spider  veins  and for use in hair
removal.  The use of  microwave  for hair  removal is based  upon the  selective
heating of hair  follicles  while cooling the surface of the skin to protect the
epidermis. MMC has used computer modeling and laboratory studies to optimize the
system  for hair  removal.  Preclinical  studies  have  shown  effectiveness  in
destroying follicles while maintaining the integrity of the skin surface.

     MMC's  microwave  system for hair removal has completed  Phase III clinical
trials and the Company has sufficient data to submit for FDA approval.  In April
1999, the Company filed the first in a series of FDA 510(k)  submissions for its
proprietary  microwave  technology for minimally invasive cosmetic surgery.  The
510(k) will focus on the use of the Company's microwave device for hair removal.
It typically takes 90 to 120 days for the FDA to review the application.

RESULTS OF OPERATIONS

     The financial  statements  for 1999 present the combined  activities of the
Company and MMC.

     The financial  statements  for 1998 present the combined  activities of the
Company, MMC, and P&H for the first quarter.

     During the three months ended March 31, 1999, the management of the Company
received $105,000. The President received $36,000, the Chairman received $45,000
and the Secretary received $24,000.

     Net loss for the three months ended March 31, 1999 was $389,566 compared to
income  of  $1,957,091  for the same  period in 1998.  The  Company  expects  to
generate revenue in late 1999.




<PAGE>



     General and  administrative  expenses  for the three months ended March 31,
1999 were $254,535 compared to $1,055 for the same period in 1998.

     Research and development  expenses were $117,515 for the three months ended
March 31, 1999 compared to $192,157 for the same period in 1998.

     Depreciation and amortization expenses for the three months ended March 31,
1999 were $24,672 compared to $25,282 for the same period in 1998.

Impact of the Year 2000 Issue

     The "Year 2000 problem" arose because many existing  computer  programs use
only the last two digits to refer to a year. Therefore,  these computer programs
do not  properly  recognize a year that begins with "20" instead of the familiar
"19".  If not  corrected,  many  computer  applications  could  fail  or  create
erroneous  results.  The extent of the potential impact of the Year 2000 problem
is not yet  known,  and if not  timely  corrected,  it could  affect  the global
economy.  The Company believes that its computer  programs are Y2K compliant and
does not expect to be adversely affected by the issue.

                           PART II - OTHER INFORMATION

Item 6. Exhibits and Reports on Form 8-K

         (a)      Exhibits
                  99-1 Financial Statements as of March 31, 1999.
                  Financial Data Schedule

         (b)      Reports on Form 8-K
                  None.


                                   SIGNATURES

     Pursuant to the  requirements  of the  Securities and Exchange Act of 1934,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned thereunto duly authorized.




DATED: May 24, 1999
                                     Grace Sim, Secretary/Treasurer and Director




<PAGE>



                        MW MEDICAL, INC. AND SUBSIDIARIES
                           CONSOLIDATED BALANCE SHEETS



<TABLE>
<CAPTION>
                                                                                                 March 31,         December 31,
                                                                                                   1999                1998
                                                                                                (Unaudited)          (Audited)
                                                                                             -----------------  ------------------
ASSETS
   CURRENT ASSETS
<S>                                                                                          <C>                <C>
     Cash and cash equivalents                                                               $         736,407  $          890,283
     Receivable - former parent                                                                        150,000             200,000
     Receivable - P & H sale                                                                            63,674              21,625
     Other receivables                                                                                   1,800               2,000
     Prepaid expense and other current assets                                                            7,298              61,282
                                                                                             -----------------  ------------------
                                                                      TOTAL CURRENT ASSETS             959,179           1,175,190

   PROPERTY, PLANT, & EQUIPMENT                                                                         42,780              67,392

   OTHER ASSETS
     Receivable - P&H sale                                                                             119,451             161,500
     Organization costs                                                                                    340                 400
                                                                                             -----------------  ------------------
                                                                                                       119,791             161,900
                                                                                             -----------------  ------------------

                                                                                             $       1,121,750  $        1,404,482
                                                                                             =================  ==================

LIABILITIES & EQUITY
   CURRENT LIABILITIES
     Accounts payable                                                                        $          73,674  $           70,766
     Income taxes payable                                                                                  800               1,600
     Accrued expenses                                                                                    1,490               1,038
     Accrued expenses - related party                                                                  135,738             132,714
                                                                                             -----------------  ------------------
                                                                 TOTAL CURRENT LIABILITIES             211,702             206,118
                                                                                             -----------------  ------------------

                                                                         TOTAL LIABILITIES             211,702             206,118

STOCKHOLDERS' EQUITY
   Common stock $.001 par value:
     Authorized - 100,000,000 shares
     Issued and outstanding 15,873,929 shares (15,723,929 in 1998)                                      15,874              15,724
     Additional paid in capital                                                                      1,157,097           1,055,997
   Retained earnings (deficit)                                                                        (262,923)            126,643
                                                                                             -----------------  ------------------
                                                                TOTAL STOCKHOLDERS' EQUITY             910,048           1,198,364
                                                                                             -----------------  ------------------

                                                                                             $       1,121,750  $        1,404,482
                                                                                             =================  ==================

</TABLE>


                                      F - 1

<PAGE>



                        MW MEDICAL, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (Unaudited)


<TABLE>
<CAPTION>
                                                                       Three months ended
                                                                            March 31,
                                                                     1999             1998
                                                                -------------     -------------
<S>                                                             <C>               <C>
General & administrative expenses                               $     254,535     $       1,055
Depreciation and amortization                                          24,672            25,282
Research and development                                              117,515           192,157
                                                                -------------     -------------
                                                                      396,722           218,494
                                                                -------------     -------------

                                        NET OPERATING (LOSS)         (396,722)         (218,494)

OTHER INCOME (EXPENSE)
   Interest income                                                      7,956                47
   Debt cancellation - former parent                                        0         2,169,806
   Fee - former parent                                                      0           200,000
                                                                -------------     -------------
                                                                        7,956         2,369,853

Income (loss) from continuing operations before
   income taxes                                                      (388,766)        2,151,359
Income tax expense                                                        800               800
                                                                -------------     -------------

                                    NET INCOME (LOSS) BEFORE
                                     DISCONTINUED OPERATIONS         (389,566)        2,150,559

Discontinued operations:
   Operations of subsidiary sold 4/1/98                                     0          (193,468)
                                                                -------------     -------------

                                           NET INCOME (LOSS)    $    (389,566)    $   1,957,091
                                                                =============     =============

Net income (loss) per weighted average share                    $        (.02)    $         .14
                                                                =============     =============

Weighted average number of common shares used
   to compute net income (loss) per weighted
   average share                                                   15,788,929        14,223,929
                                                                =============     =============
</TABLE>



                                      F - 2

<PAGE>



                        MW MEDICAL, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (Unaudited)


<TABLE>
<CAPTION>
                                                                                                   Three months ended
                                                                                                        March 31,
                                                                                               1999                  1998
                                                                                        ------------------    ------------------
OPERATING ACTIVITIES
<S>                                                                                     <C>                   <C>
     Net income (loss)                                                                  $         (389,566)   $        1,957,091
     Adjustments to reconcile net income (loss) to cash used
       by operating activities:
         Depreciation and amortization                                                              24,672                63,859
         Debt cancelled                                                                                  0            (2,169,806)
     Changes in assets and liabilities:
         Accounts receivable                                                                        50,200              (188,097)
         Inventories                                                                                     0                80,636
         Prepaid expenses and other                                                                 53,984                13,053
         Accounts payable and accrued expenses                                                       6,384               (30,019)
         Income taxes payable                                                                         (800)                    0
                                                                                        ------------------    ------------------

                                               NET CASH USED BY OPERATING ACTIVITIES              (255,126)             (273,283)

INVESTING ACTIVITIES
     Loan - other                                                                                        0                 1,488
     Loan - related party                                                                                0                     0
     Purchase of equipment                                                                               0                (1,796)
     Deposits                                                                                            0                (2,243)
                                                                                        ------------------    ------------------

                                               NET CASH USED BY INVESTING ACTIVITIES                     0                (2,551)

FINANCING ACTIVITIES
     Borrowings - former parent                                                                          0               170,000
     Sale of common stock                                                                          101,250                     0
     Deposits                                                                                            0                37,000
     Principal payments on debt                                                                          0                (9,951)
                                                                                        ------------------    ------------------

                                                                   NET CASH PROVIDED
                                                             BY FINANCING ACTIVITIES               101,250               197,049
                                                                                        ------------------    ------------------

                                                                  (DECREASE) IN CASH
                                                                AND CASH EQUIVALENTS              (153,876)              (78,785)

     Cash and cash equivalents at beginning of period                                              890,283               387,982
                                                                                        ------------------    ------------------

                                          CASH AND CASH EQUIVALENTS AT END OF PERIOD    $          736,407    $          309,197
                                                                                        ==================    ==================

SUPPLEMENTAL INFORMATION
     Cash paid for interest                                                             $                0    $            9,824
     Cash paid for income taxes                                                                      1,600                   800

</TABLE>


                                      F - 3